Learn how the INNOVANCE® VWF Ac assay1 supports simplified testing and reliable results.
The INNOVANCE VWF Ac assay1 directly determines real activity of VWF. Due to the gain-of-function mutations, VWF binding to GPIb does not require ristocetin (VWF:GPIbM)2 and is therefore less susceptible to effects of certain polymorphism variants.
INNOVANCE VWF Ac assay1 shows excellent correlation with the ristocetin cofactor-based BC von Willebrand assay.
A functional assay is the preferred screening method for detecting quantitative as well as qualitative defects of von Willebrand factor.3
The assay employs a liquid, ready-to-use reagent that requires no stirring.
After the positive experience we had using this assay in a study, we as caregivers in the U.S. are urgently waiting to use the INNOVANCE® VWF Ac1 assay to diagnose our patients as we believe it supports improved von Willebrand disease (VWD) diagnosis and patient management, particularly now given the new recommendations from the ASH ISTH NHF WFH 2021 guidelines on the diagnosis of VWD.
INNOVANCE VWF Ac assay is under review by FDA as a de novo classification request. An approval is pending and the product is not yet commercially available in the United States.
Bodo I, et al. Platelet dependent von Willebrand factor activity. Nomenclature and methodology:communication from the SSC of the ISTH. J Thromb Haemost 2015;13:1345–50.
James PD, et al. ASH ISTH NHF WFH 2021 guidelines on the diagnosis of von Willebrand disease. 2021 Jan 12 [published online].
INNOVANCE, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. Sysmex is
a trademark of the Sysmex Corporation. All other trademarks and brands are the property of their respective owners.
Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.